[Flashglucose monitoring system (Freestyle Libre, Abbott), report updated April 8 2020]
N. Jobin, S. Arbour et al.
Record ID 32018000806
French
Original Title:
Système flash de surveillance du glucose (FreeStyle Libre, Abbott), avis mise à jour 8 avril 2020
Authors' objectives:
The Institut national d’excellence en santé et en services sociaux (INESSS), at the
request of the ministère de la Santé et des Services sociaux (MSSS), evaluated the
relevance of reimbursing Freestyle LibreMC (Abbott) flash glucose monitoring systems
(FGMS) under the prescription drug insurance plan (RGAM).
FGMS is a flash (or intermittent) real-time glucose level monitoring device. In Canada, its
current indication is approved for measuring the glucose from interstitial fluids in adults of
at least 18 years of age with at least two (2) years of experience in diabetes selfmanagement.
Authors' recommendations:
The Institut national d’excellence en santé et en services sociaux (INESSS), considering
all the criteria laid down by law, recommends to the Minister of Health and Social
Services to enter FreeStyle LibreMC on the list of the prescription drug insurance plan
(RGAM) for blood glucose self-monitoring for patients under insulin treatment, provided
that the following condition is met.
Condition
Easing the economic burden
If the economic burden is not lessened, the INESSS recommends to enter FreeStyle
LibreMC on the list of exception drugs in accordance with the proposed recognized
payment indication.
Authors' methods:
Prior to delivering this notice, a systematic review of relevant literature was completed to
identify evidence-based findings needed for assessing and completing the information
provided by the manufacturer. Then, panels of patients (users and non-users of the
technology in question) and clinicians with expertise in diabetes management were set
up for gathering experiential and contextual data to help understand various viewpoints
on FGMS; hence, criteria for diversifying the individuals to be consulted were defined and
established for each panel to highlight potential advantages, disadvantages and
concerns linked to FGMS use. Also, an economic evaluation and a budget impact
analysis were conducted. All the data gathered and delivered by the project team was
submitted to the Standing Scientific Committee on Entry on the List of Medications
(CSEMI) for deliberation on therapeutic values of the FGMS prior to formulating
recommendations.
Details
Project Status:
Completed
Year Published:
2018
URL for published report:
https://www.inesss.qc.ca/fileadmin/doc/INESSS/Rapports/Technologies/INESSS_FreeStyle_avis_EnglishSummary.pdf
Requestor:
Minister of Health
English language abstract:
An English language summary is available
Publication Type:
Full HTA
Country:
Canada
Province:
Quebec
MeSH Terms
- Diabetes Mellitus, Type 1
- Diabetes Mellitus, Type 2
- Blood Glucose
- Blood Glucose Self-Monitoring
- Diabetes Mellitus
- Adult
- Hypoglycemia
Keywords
- Diabetes
Contact
Organisation Name:
Institut national d'excellence en sante et en services sociaux
Contact Address:
L'Institut national d'excellence en sante et en services sociaux (INESSS) , 2021, avenue Union, bureau 10.083, Montreal, Quebec, Canada, H3A 2S9;Tel: 1+514-873-2563, Fax: 1+514-873-1369
Contact Name:
demande@inesss.qc.ca
Contact Email:
demande@inesss.qc.ca
Copyright:
Gouvernement du Québec
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.